



RECEIVED


MAR 14 2003

Amtd F/#2441
J 3-17-03653

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on March 3, 2003.

TECH CENTER 1600/2900

AMENDMENT UNDER 37 C.F.R. § 1.111
Examining Group 1653
Patent Application
Docket No. GIR-T100
Serial No. 09/639,859


Frank C. Eisenschenk, Ph.D. Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10

Examiner : Chih Min Kam
Art Unit : 1653
Applicants : Leonard S. Girsh
Serial No. : 09/639,859
Filed : August 16, 2000
Confirm. No. : 2441
For : Therapeutic Stem Cell Growth Factor Composition, Anti-inflammatory Composition and Uses Thereof

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT UNDER 37 C.F.R. § 1.111

In response to the Office Action dated December 2, 2002, please amend the above-identified application as follows:

In the Specification

Please substitute the following paragraph for the paragraph found at page 9, line 4:

Figure 1 is a schematic drawing of a liver illustrating the locus of congenital biliary atresia disease being close to the location of stem cells and in approximately the area of believed therapeutic activity. Biliary atresia is evidenced by a sheet of periductular inflammation and fibrosis. Also shown on this H&E slide is extensive periductule inflammation. This inflammatory obstruction also